Tolmetin Sodium (Tolmetin Sodium) Patent Expiration, LOE Window & CMS Spending
Tolmetin Sodium (Tolmetin Sodium) by Atland Pharmace: Multi-Source Generic Molecule, 2 AB generics, $8.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Atland Pharmace |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $8.2M |
| 2024 Medicare Part D Spend | $2.7M |
| 2024 Medicaid Spend | $5.5M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 52.3% 2-yr change) |